Clinical trials: Dendritic Cell
Glioblastoma
Dendritic Cell Immunotherapy Against Cancer Stem Cells in Glioblastoma Patients Receiving Standard Therapy
Open, randomized study of a trivalent dendritic cell therapy compared to standard therapy in primary treated patients with IDH wild-type, MGMT-promotor methylated glioblastoma.
- Trial name
- DEN-STEM (NCT03548571)
- Testing
- Dendritic cell immunization, Adjuvant temozolomide
- Where
- Norway
- Volunteers
- 60 people
- Sponsor
- Oslo University Hospital
Malignant Glioma
Dendritic Cell (DC) Activated Cytokine-induced Killer Cell (DCIK) Combined With DC Treatment for Glioma
Malignant gliomas are very aggressive and among the most common of brain tumors. A diagnosis carries with it a median survival of approximately 12 months, with 90 - 95% of patients surviving less than 2 years.
- Trial name
- NCT01235845
- Testing
- Biological: DC activated CIK combined with DC
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Qingdao University
Kidney Transplant, Renal Transplant Recipients
Allogeneic Regulatory Dendritic Cell (DCreg) Renal Study
This study will evaluate the safety and feasibility of treatment involving a single infusion of donor-derived regulatory dendritic cells (DCreg) in first time, living donor renal transplant recipients.
- Trial name
- RTB-006 (NCT03726307)
- Testing
- DCreg: 0.5 million cells/kg+SOC, DCreg: 1.2 million cells/kg+SOC, DCreg:2.5 to 5.0 million cells/kg+SOC
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Angus W. Thomson PhD DSc
Multiple Sclerosis, Neuromyelitis Optica
Treatment of Multiple Sclerosis and Neuromyelitis Optica With Regulatory Dendritic Cell: Clinical Trial Phase 1 B
First in human study to assess the tolerability and safety profile of treatment with dendritic cell in patients with multiple sclerosis or neuromyelitis optica.
- Trial name
- NCT02283671
- Testing
- Tolerogenic Dendritic cells loaded with myelin peptides
- Where
- Spain
- Volunteers
- 20 people
- Sponsor
- Sara Varea
Non-Hodgkin's Lymphoma
High Dose CHOP in Lymphoma
The study hypothesis is that intensification of CHOP by dose escalation of the most active drugs in the combination will improve treatment outcome.
- Trial name
- NCT00192764
- Testing
- high-dose cyclophosphamide
- Where
- Israel
- Volunteers
- 45 people
- Sponsor
- Rambam Health Care Campus
Colo-rectal Cancer, Liver Metastases
Radiogenomic Profiling of Dendritic Cells and Macrophages to Predict Recurrence in Colorectal Liver Metastasis
The RaP-DMac-LiMe study (Radiogenomic Profiling of Dendritic Cells and Macrophages to Predict Recurrence in Colorectal Liver Metastasis) is a monocentric, non-profit observational study promoted by Fondazione Policlinico…
- Conditions
- Colo-rectal Cancer, Liver Metastases, Colon Cancer
- Trial name
- RaP-DMac-LiMe (NCT07744139)
- Testing
- Radiogenomic and Immune Profiling, Prospective Radiogenomic and ctDNA Profiling
- Volunteers
- 210 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
DLBCL - Diffuse Large B Cell Lymphoma
Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma Non-transplant Eligible Patients in Italy (PRO-MIND)
The PRO-MIND study is an Italian, multicenter, prospective observational cohort study to evaluate the effectiveness and the safety of tafasitamab in combination with lenalidomide followed by tafasitamab monotherapy in patient…
- Trial name
- NCT06299553
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- Incyte Biosciences Italy S.r.l
Recurrent Respiratory Papillomatosis
Autologous Dendritic Cell Vaccine For Recurrent Respiratory Papillomatosis (RRP) Patients
The purpose of this study is to evaluate the safety and immunogenicity of autologous DC vaccine in recurrent respiratory papillomatosis patients
- Trial name
- NCT07317154
- Testing
- Autologous HPV6 E6-and E7-derived peptide-loaded dendritic cell
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Mayo Clinic
Melanoma (Skin)
Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma
RATIONALE: Vaccines made from melanoma cells may make the body build an immune response to and kill tumor cells. Colony-stimulating factors such as GM-CSF may increase the number of immune cells found in the bone marrow or…
- Trial name
- NCT00003222
- Testing
- aldesleukin, gp100 antigen, incomplete Freund's adjuvant
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Virginia
Metastatic Colorectal Cancer
Alpha-type-1 Dendritic Cell-based Vaccines in Patients With Metastatic Colorectal Cancer
The purpose of this study is to evaluate the administration, safety and immunologic effectiveness of an experimental vaccine for colorectal cancer patients.
- Trial name
- NCT00558051
- Testing
- DC-based vaccine
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Pawel Kalinski
Prostate Cancer
PROvenge Treatment and Early Cancer Treatment
The PROTECT-PROvenge Treatment and Early Cancer Treatment trial was a Phase III trial for patients with hormone sensitive prostate cancer. The study was conducted at over 15 participating centers throughout the US.
- Trial name
- PROTECT (NCT00779402)
- Testing
- Control, Sipuleucel-T
- Where
- 18 sites in United States
- Volunteers
- 176 people
- Sponsor
- Dendreon
Newly Diagnosed Glioblastoma
Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Newly Diagnosed Glioblastoma
This is a single-arm, open-label phase II clinical trial in which approximately 55 patients with newly diagnosed glioblastoma (GBM) will be enrolled with the intent to receive an autologous dendritic cell vaccine consisting of…
- Trial name
- NCT03400917
- Testing
- AV-GBM-1
- Where
- 8 sites in United States
- Volunteers
- 55 people
- Sponsor
- Aivita Biomedical, Inc.
Psoriasis
Role of Glucose Metabolism in Migration of Cutaneous Dendritic Cells in Psoriasis
Dendritic cells (DC) paly a key role in the induction and chronicity of psoriasis by capturing the antigenes and activating the T cell repsonse.
- Trial name
- NCT05399433
- Testing
- Biopsy and venous blood
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Lymphoma, Large-Cell
Early Evaluation of the Response of Large B Cell Non Hodgkin's Lymphoma to Chemotherapy by PET/CT
Patients affected with non-Hodgkin's large B-cell lymphoma are treated by chemotherapy. The evaluation of the response to this treatment is made by Positron Emission Tomography (PET/CT) in many centres where this technology is…
- Trial name
- NCT00256490
- Testing
- PET/CT 20 days after the first cycle of chemotherapy
- Where
- Canada
- Volunteers
- 82 people
- Sponsor
- Eric Turcotte
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant
This phase I/II trial studies whether stopping cyclosporine before mycophenolate mofetil is better at reducing the risk of life-threatening graft-versus-host disease (GVHD) than the previous approach where mycophenolate mofetil…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT00078858
- Testing
- fludarabine phosphate, total-body irradiation, nonmyeloablative allogeneic hematopoietic stem cell transplantation
- Where
- 10 sites in United States, Germany and 1 more
- Volunteers
- 37 people
- Sponsor
- Fred Hutchinson Cancer Center
Ovarian Carcinoma
PEP-DC and OC-DC Vaccine in High Grade Serous Ovarian Carcinoma
Single center, phase I/II randomized 2-arm study, evaluating two different vaccination regimens combined with low-dose cyclophosphamide in patients with advanced high grade serous ovarian carcinoma (HGSOC): Arm A patients will be…
- Trial name
- CHUV-OVACURE (NCT05714306)
- Testing
- PEP-DC1, OC-DC, PEP-DC2
- Sponsor
- Centre Hospitalier Universitaire Vaudois
Immune Modulation, Tuberculosis
CD8 Reactivity to Microorganisms in Blood and Breast Milk
Background: When a person is exposed to something that causes an infection, the body sends a type of cell called CD8 T cells to attack it. Those cells are also found in breast milk.
- Conditions
- Immune Modulation, Tuberculosis, Leprosy, Pertussis
- Trial name
- NCT03084614
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Breast Cancer
Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Women With Locally Recurrent or Metastatic Breast Cancer
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming…
- Trial name
- NCT00088985
- Testing
- therapeutic autologous dendritic cells, trastuzumab, vinorelbine ditartrate
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Advanced Solid Tumor, Cancer
Personalized Neoantigen-pulsed Autologous Dendritic Cell Injections for Malignant Solid Tumors
This is a prospective, single-center, open-label, real-world clinical study designed to evaluate the safety, efficacy, and immunogenicity of Personalized neoantigen-pulsed autologous dendritic cell Injections （ZSNeo-DC）in…
- Conditions
- Advanced Solid Tumor, Cancer, Malignant Solid Tumor
- Trial name
- ZSNeo-DC-RWS (NCT07752953)
- Testing
- Personalized neoantigen-pulsed autologous dendritic cell Injections （ZSNeo-DC）, Immune Checkpoint Inhibitors
- Where
- China
- Volunteers
- 100 people
- Sponsor
- ZSky Biotech Inc
Hymenoptera Venom Allergy
Regulation of Blood Dendritic Cells During Immune Therapy for Hymenoptera Venom Allergy
Dendritic cells (DC) play a key role in the pathogenesis of allergic diseases. The regulation of blood dendritic cells in patients with hymenoptera venom allergy before and during immune therapy is unknown.
- Trial name
- NCT00947908
- Testing
- Hymenoptera venom
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- University of Rostock